Morningstar

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Provided by GlobeNewswire

BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London.

2026 Jefferies Global Healthcare Conference
Dates: Monday, November 16 & Tuesday, November 17, 2026
Format: Fireside chat and 1x1 meetings
Fireside Chat: Monday, November 16, 2026 from 4:00 – 4:25 p.m. GMT
Location: London, UK

If you are interested in meeting with the Minerva team during the conference, please reach out to your respective Jefferies representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

3 Stocks to Sell and 3 Stocks to Buy for November

Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.
David Sekera, CFA and Sarah Hansen

3 of the Best Dividend Stocks to Own

These dividend stocks with economic moats offer durable payouts.
Susan Dziubinski

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

These Overvalued Stocks Have Plenty of Room to Fall

Why investors should be wary of a refiner and financial-services stock trading well above our fair value estimates.
David Sekera, CFA, Sarah Hansen, and Jess Bebel

It’s Been a Long Time Since Bonds Looked This Good

Yields are up, and durations are down, tilting the risk/reward in investors’ favor.
Jeffrey Ptak, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.